Industry & Business

Diaceutics to Use Artificial Intelligence to Improve Diagnosis and Treatment of Patients

 Breaking News
  • Aramark’s Frank Gleeson Named European Industry Leader of the Year Frank Gleeson, president of Aramark Northern Europe, has been named the 2018 NACS European Industry Leader of the Year. The award, sponsored by Mondelēz International, was presented during the recent NACS Convenience Summit Europe in London. “I cannot think of a better leader to be recognised for this prestigious award. He has been one of the industry’s strongest advocates for [...]...
  • McAleer & Rushe Recognised at the Irish Construction Industry Awards Gala Northern Ireland-based developer and contractor McAleer & Rushe has been awarded the prize for ‘International Project of the Year’ at the Irish Construction Industry Awards for Global Student Accommodation’s 1000-bed Catherine House scheme in Portsmouth. The awards, now in their fifth year, recognise companies which demonstrate excellence and innovation in Ireland’s construction industry. McAleer & [...]...
  • Bord Bia’s 2018 Brexit Barometer Results The Minister for Agriculture, Food and the Marine Michael Creed TD has launched the Bord Bia 2018 Brexit Barometer, a comprehensive survey of 117 Irish food, drink and horticulture companies, representing 48% of the sector’s exporters to the United Kingdom. Over 100 senior industry representatives attended the launch in Bord Bia to hear the report findings. The purpose [...]...
  • College Group to Construct New €10 Million Biofuel Facility in County Meath College Group is to invest €10 million in building a new renewable energy facility producing biofuel from used cooking oil and animal fats in north County Meath. The investment is supported by the Irish government through Enterprise Ireland. The new 25 million litre purpose-built plant will be set on a 47.5 acre site and will [...]...
  • Irish Global Packaging Solutions Company Announces €27 Million Investment Zeus, the Irish-owned global packaging solutions company, has announced a €27 million investment in new premises in Dublin and the UK. The investment will also lead to the creation of 80 jobs. An investment of €15 million will see Zeus’ Dublin presence double in size to 250,000 sq ft, with the creation of 50 new jobs. Zeus [...]...

Diaceutics to Use Artificial Intelligence to Improve Diagnosis and Treatment of Patients

Diaceutics to Use Artificial Intelligence to Improve Diagnosis and Treatment of Patients
March 07
09:26 2018

Diaceutics, the Irish company helping patients to receive potentially lifesaving medicine through better diagnostic testing, has announced a collaboration with computer hardware manufacturer Lenovo, and chip manufacturer Intel. The collaboration will enable Diaceutics to leverage their vast proprietary database of patient testing data in a revolutionary way.

Using artificial intelligence (AI) to see whether patients can be grouped according to diagnostic test information, the company is hopeful that this data can help identify ways to improve diagnosis, treatment and outcomes for patients with similar characteristics.

Utilising one of the most powerful workstations on the planet, with the Lenovo ThinkStation P920 powered by Intel Xeon Scalable processors, and a vast amount of complex testing data from hundreds of clinical laboratories, Diaceutics is aiming to get the right medicine to the right individuals at the right time by classifying patient groups and disease patterns.

After a number of biomarkers covering a variety of tumours and cancer types have been inputted, the machine learning system will be able to identify similarities and patterns within the testing data and highlight what is happening among groups of patients. Essentially, the organisation of this information could mean that at-risk patients can be identified, diagnosed and treated much faster.

Considering that an estimated 78,000 cancer patients are not properly tested each year in the United States and therefore are being denied access to potentially lifesaving medication, this collaboration could further transform the area of personalised medicine. Diaceutics has given more than half a million patients the best possible chance of getting to better treatment through better testing.  The findings from the collaboration will be presented at a series of upcoming conferences.

Peter Keeling (pictured), chief executive officer of Diaceutics, said: “Artificial intelligence can make a very strong and positive impact on precision medicine and we are excited to be moving the boundaries with this highly innovative technology. We can now look at data in a novel way. No longer will we only be  making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates.

“This collaboration is a major step in our mission to help patients, by helping them find the right precision medicine at the right time. We are using artificial intelligence to enable the world to unlock the true life changing promise of precision medicine.”

About Author

admin

admin

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4